Under certain circumstances someone might be able to obtain experimental treatments, also called investigational new drugs, if they cannot participate in a clinical trial. The Food and Drug Administration allows manufacturers of investigational new drugs to provide the agents to someone with a serious disease who might benefit from the treatment under what is called “expanded access.” Also, someone might be ineligible for one trial, but be eligible for another one.